文献速递肺结节与肺癌

I期肺癌手术与放疗的意向性治疗分析

Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis.
PubMed 文献 · Eur Respir J · 2019-06-20

该回顾性意向性治疗分析纳入单个英国大型中心468例 presumed I期肺癌患者(手术316例,SABR 99例),比较总生存、癌症特异性生存及癌症与治疗相关联合生存。多变量分析显示SABR总生存劣于手术(HR 1.84,95%CI 1.32-2.57),但癌症特异性生存(HR 1.47,95%CI 0.80-2.69)及联合生存(HR 1.27,95%CI 0.74-2.17)无差异;SABR非癌症死亡显著更高(亚分布风险比2.16,95%CI 1.41-3.32)。

要点

  • SABR总生存劣于手术,但癌症特异性生存无差异。
  • SABR非癌症相关死亡显著高于手术。
  • 癌症与治疗相关联合死亡在两种治疗间无差异。

核心结论

  • 在该意向性治疗分析中,SABR与手术的癌症特异性生存无差异。
  • SABR总生存劣于手术,主要因非癌症相关死亡更高。

研究设计与样本

  • 回顾性意向性治疗分析,纳入单个英国大型中心presumed I期肺癌患者468例(手术316例,SABR 99例)。
  • 采用Cox比例风险及Fine-Gray竞争风险模型校正混杂变量。

主要发现

  • 多变量Cox模型显示SABR总生存劣于手术(HR 1.84,95%CI 1.32-2.57)。
  • 癌症特异性生存无差异(SABR HR 1.47,95%CI 0.80-2.69)。
  • 癌症与治疗相关联合生存无差异(SABR HR 1.27,95%CI 0.74-2.17)。
  • Fine-Gray竞争风险多变量模型显示癌症与治疗相关死亡无差异(亚分布风险比1.03,95%CI 0.59-1.81)。
  • SABR非癌症相关死亡显著高于手术(亚分布风险比2.16,95%CI 1.41-3.32)。

临床怎么用

  • 对于presumed I期肺癌,SABR可作为手术的替代选择,尤其关注癌症特异性生存时。
  • 需权衡SABR较高的非癌症相关死亡风险,个体化选择治疗。

局限性

  • 回顾性设计,可能存在选择偏倚和混杂。
  • 样本来自单中心,外推性受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Surgery is the standard of care for early-stage lung cancer, with stereotactic ablative body radiotherapy (SABR) a lower morbidity alternative for patients with limited physiological reserve. Comparisons of outcomes between these treatment options are limited by competing comorbidities and differences in pre-treatment pathological information. This study aims to address these issues by assessing both overall and cancer-specific survival for presumed stage I lung cancer on an intention-to-treat basis. METHODS: This retrospective intention-to-treat analysis identified all patients treated for presumed stage I lung cancer within a single large UK centre. Overall survival, cancer-specific survival, and combined cancer and treatment-related survival were assessed with adjustment for confounding variables using Cox proportional hazards and Fine-Gray competing risks analyses. RESULTS: 468 patients (including 316 surgery and 99 SABR) were included in the study population. Compared with surgery, SABR was associated with inferior overall survival on multivariable Cox modelling (SABR HR 1.84 (95% CI 1.32-2.57)), but there was no difference in cancer-specific survival (SABR HR 1.47 (95% CI 0.80-2.69)) or combined cancer and treatment-related survival (SABR HR 1.27 (95% CI 0.74-2.17)). Combined cancer and treatment-related death was no different between SABR and surgery on Fine-Gray competing risks multivariable modelling (subdistribution hazard 1.03 (95% CI 0.59-1.81)). Non-cancer-related death was significantly higher in SABR than surgery (subdistribution hazard 2.16 (95% CI 1.41-3.32)). CONCLUSION: In this analysis, no difference in cancer-specific survival was observed between SABR and surgery. Further work is needed to define predictors of outcome and help inform treatment decisions.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Spencer KL, Kennedy MPT, Lummis KL, et al. Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis. Eur Respir J. 2019. PMID: 30635294. doi:10.1183/13993003.01568-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。